Patent · US Active

Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin

US10912823B2 · kind B2 · utility

0Cited by
4References
20Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 30, 2018
Grant dateFeb 9, 2021
Priority date
Expiry dateMay 30, 2038

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61K2800/91
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Methods for treating melanin-related afflictions of the skin, such as hyperpigmentation, are provided. The methods comprise administering a composition comprising BoNT/DC.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.